Table 3.
Clinical and treatment characteristics among study groups based on birth weight and gestational age
| Birth weight | Gestational age | ||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| <=1500 gr | P | 1501 + gr | P | <=30 w | P | 31 + wP | P | ||||||||||||
| HDP (578 eyes) |
GDM (376 eyes) |
GDM-HDP (124 eyes) |
HDP (532 eyes) |
GDM (588 eyes) |
GDM-HDP (144 eyes) |
HDP (308 eyes) |
GDM (330 eyes) |
GDM-HDP (76 eyes) |
HDP (802 eyes) |
GDM (614 eyes) |
GDM-HDP (192 eyes) |
||||||||
| Severe ROP | 100 (17.3%) | 103 (27.4%) | 24 (19.4%) | 0.001 | 10 (1.9%) | 24 (4.2%) | 13 (9.0%) | < 0.001 | 79 (25.6%) | 112 (33.9%) | 25 (32.9%) | 0.065 | 31 (3.9%) | 15 (2.4%) | 12 (6.3%) | 0.041 | |||
| Treatment requirement | 141 (24.4%) | 131 (34.8%) | 30 (24.2%) | 0.001 | 13 (2.4%) | 34 (6.0%) | 15 (10.4%) | < 0.001 | 111 (36%) | 144 (43.6%) | 33 (43.4%) | 0.125 | 43 (5.4%) | 21 (3.4%) | 12 (6.3%) | 0.133 | |||
| Retreatment after IVB or laser |
9/135 (6.7%) |
17/129 (13.2%) | 6/28 (21.4%) | 0.042 | 0/13 | 2/32 (6.3%) | 0/15 | 0.404 | 5/107(4.7%) | 19/140 (13.6%) | 6/31 (19.4%) | 0.022 | 4/41 (9.8%) | 0/21 | 0/12 | 0.182 | |||
HDP: Hypertensive disorders of pregnancy; GDM: Gestational diabetes mellitus; ROP: Retinopathy of prematurity; IVB: Intravitreal bevacizumab